Drug Trial Radar · NCT05686642
Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke
Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Apr 6, 2023
Primary completion
Dec 10, 2026
Study completion Dec 12, 2026
Sponsor
- Lead sponsor
- Shanghai Pharmaceuticals Holding Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II clinical study is designed to evaluate the safety and efficacy of LT3001 in the treatment of acute ischemic stroke
Conditions
- Acute Ischemic Stroke
Interventions
LT3001 Drug:high doseDrug
Administered by intravenous infusion.
PlaceboDrug
Administered by intravenous infusion.
LT3001 Drug:low doseDrug
Administered by intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence Adverse EventsTime frame: Approximately 2 years
Locations
28 sites in 1 country. Site status is shown where the registry gives one.
Beijing Tiantan Hospital, Capital Medical University
Beijing, China · Recruiting
Beijing Tsinghua Changgung Hospital
Beijing, China · Recruiting
Linfen Central Hospital
Linfen, China · Recruiting
Linfen People's Hospital
Linfen, China · Recruiting
Nanshi Hospital of Nanyang
Nanyang, China · Recruiting
Shanghai Pudong Hospital
Shanghai, China · Recruiting
Central People's Hospital of Zhanjiang
Zhanjiang, China · Recruiting
Beijing Luhe Hospital Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China · Recruiting
Luoyang Third People's Hospital
Luoyang, He'nan, China · Recruiting
Harrison International Peace Hospital
Hengshui, Hebei, China · Recruiting
Daqing Oilfield General Hospital
Daqing, Heilongjiang, China · Recruiting
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China · Recruiting
The First Affiliated Hospital of Baotou Medical College
Baotou, Inner Mongolia, China · Recruiting
Inner Mongolia Baogang Hospital
Baotou, Inner Mongolia, China · Recruiting
Huai'an Second People's Hospital
Huai'an, Jiangsu, China · Recruiting
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China · Recruiting
Pingxiang People's Hospital
Pingxiang, Jiangxi, China · Recruiting
The First Bethune Hospital of Jilin University
Changchun, Jilin, China · Recruiting
Beipiao Central Hospital
Chaoyang, Liaoning, China · Recruiting
Liaocheng People's Hospital
Liaocheng, Shandong, China · Recruiting
Xi'an Gaoxin Hospital
Xi’an, Shanxi, China · Recruiting
Yan'an University Xianyang Hospital
Xianyang, Shanxi, China · Recruiting
The Third Hospital of Mianyang
Mianyang, Sichuan, China · Recruiting
Zhejiang Hospital
Hangzhou, Zhejiang, China · Recruiting
Taizhou Municipal Hospital
Taizhou, Zhejiang, China · Recruiting
Taizhou First People's Hospital
Taizhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.